May 1 (Reuters) - Industrial equipment maker IDEX Corp ( IEX )

on Thursday beat Wall Street estimates for first-quarter

profit and revenue, driven by a sustained recovery in the demand

for its health and science-related products.

Demand for such products has been rising as sellers continue

to restock their inventory after a prolonged period of drawdowns

caused by large stockpiles accumulated during the COVID-19

pandemic.

Sales at IDEX's ( IEX ) health and sciences technology segment,

which makes components used in clinical diagnostics, drug

discovery, food-processing industry, among others, rose 10% from

a year ago.

The company maintained its full-year earnings forecast of

$8.10 and $8.45 per share, citing an "additional $20 million of

cost containment actions to mitigate potential tariff-related

volume pressure."

"We recognize that there are likely to be increasing levels

of customer caution and slower decision-making ahead," CEO Eric

Ashleman said.

IDEX ( IEX ) expects its second-quarter adjusted profit to be

between $1.95 and $2.05 per share, compared with analysts'

average estimate of $2.10 per share, according to data compiled

by LSEG.

The company's first-quarter earnings stood at $1.75 per

share, above market estimates of $1.63.

Total revenue for the three months ended March 31 was $814.3

million, surpassing estimates of $807.2 million.